Elizabeth D Tate

Summary

Affiliation: Southern Illinois University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG
    Michael R Pranzatelli
    The National Pediatric Myoclonus Center, Departments of Neurology and Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois 62702, USA
    Mov Disord 17:1387-90. 2002
  2. ncbi request reprint Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome
    Elizabeth D Tate
    Southern Illinois University, School of Medicine, Division of Child and Adolescent Neurology, PO Box 19643, Springfield, IL 62794 9643, USA
    J Pediatr Oncol Nurs 22:8-19. 2005
  3. doi request reprint Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome
    Elizabeth D Tate
    National Pediatric Myoclonus Center, and Departments of Neurology and Statistics and Research Consulting, Southern Illinois University School of Medicine, Springfield, IL 62794, USA
    J Child Neurol 27:875-84. 2012
  4. doi request reprint B cell depletion therapy for new-onset opsoclonus-myoclonus
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
    Mov Disord 25:238-42. 2010
  5. pmc BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy
    Michael R Pranzatelli
    Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Laboratory, and Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794 9643, USA
    J Neuroinflammation 10:10. 2013
  6. ncbi request reprint Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Department of Neurology, SouthernIllinois University School of Medicine, Springfield, Illinois, USA
    J Child Neurol 24:316-22. 2009
  7. ncbi request reprint CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, P O Box 19643, Springfield, IL 62794 9643, USA Department of Neurology, SouthernIllinois University School of Medicine, P O Box 19643, Springfield, IL 62794 9643, USA Electronic address
    Cytokine 64:331-6. 2013
  8. ncbi request reprint Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
    J Pediatr Hematol Oncol 28:585-93. 2006
  9. doi request reprint Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
    J Pediatr Hematol Oncol 32:e167-72. 2010
  10. doi request reprint Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
    J Clin Immunol 30:106-13. 2010

Detail Information

Publications26

  1. ncbi request reprint Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG
    Michael R Pranzatelli
    The National Pediatric Myoclonus Center, Departments of Neurology and Pediatrics, Southern Illinois University School of Medicine, Springfield, Illinois 62702, USA
    Mov Disord 17:1387-90. 2002
    ..We report on an adult with opsoclonus-myoclonus-ataxia syndrome experiencing widely spaced neurological relapses, who was followed for 41 years. His responses to treatment are described...
  2. ncbi request reprint Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome
    Elizabeth D Tate
    Southern Illinois University, School of Medicine, Division of Child and Adolescent Neurology, PO Box 19643, Springfield, IL 62794 9643, USA
    J Pediatr Oncol Nurs 22:8-19. 2005
    ..More than one half of the children had relapses. Residual behavioral, language, and cognitive problems occurred in the majority. The delay in diagnosis (11 weeks) and initiation of treatment (17 weeks) is unacceptably long...
  3. doi request reprint Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome
    Elizabeth D Tate
    National Pediatric Myoclonus Center, and Departments of Neurology and Statistics and Research Consulting, Southern Illinois University School of Medicine, Springfield, IL 62794, USA
    J Child Neurol 27:875-84. 2012
    ..This study demonstrates greater efficacy of corticotropin-based multimodal therapy compared with conventional therapy, greater response to corticotropin than corticosteroid-based therapy, and overall tolerability...
  4. doi request reprint B cell depletion therapy for new-onset opsoclonus-myoclonus
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
    Mov Disord 25:238-42. 2010
    ..Combination of rituximab with conventional agents as initial therapy was effective and safe. A controlled trial with long-term safety monitoring is indicated...
  5. pmc BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy
    Michael R Pranzatelli
    Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Laboratory, and Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794 9643, USA
    J Neuroinflammation 10:10. 2013
    ..B-cell dysregulation has been implicated but not fully characterized in pediatric opsoclonus-myoclonus syndrome (OMS), a neuroblastoma-associated neuroinflammatory disorder...
  6. ncbi request reprint Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Department of Neurology, SouthernIllinois University School of Medicine, Springfield, Illinois, USA
    J Child Neurol 24:316-22. 2009
    ..Mycophenolate mofetil did not prevent relapse. The novel effect of mycophenolate mofetil on chronically activated T cells may contribute to its efficacy in T-cell mediated neurological disorders...
  7. ncbi request reprint CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, P O Box 19643, Springfield, IL 62794 9643, USA Department of Neurology, SouthernIllinois University School of Medicine, P O Box 19643, Springfield, IL 62794 9643, USA Electronic address
    Cytokine 64:331-6. 2013
    ..Corticosteroids and ACTH were the only immunotherapies evaluated that down-regulated CCL21 production. Validation studies are needed to assess treatment biomarker status...
  8. ncbi request reprint Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
    J Pediatr Hematol Oncol 28:585-93. 2006
    ..To determine if rituximab, an anti-CD20 monoclonal antibody, reduces cerebrospinal fluid (CSF) B-cell expansion in opsoclonus-myoclonus syndrome (OMS) and results in clinical improvement...
  9. doi request reprint Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
    J Pediatr Hematol Oncol 32:e167-72. 2010
    ..They also suggest that pediatric rituximab dosing should be based on body weight, not surface area. (ClinicalTrials.gov NCT00244361)...
  10. doi request reprint Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, IL, USA
    J Clin Immunol 30:106-13. 2010
    ..The study aim was to assess whether rituximab-induced B cell ablation in CSF outlasts repopulation in blood and if there are changes in other lymphocyte subsets...
  11. ncbi request reprint Immunophenotype of blood lymphocytes in neuroblastoma-associated opsoclonus-myoclonus
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    J Pediatr Hematol Oncol 26:718-23. 2004
    ..To determine whether the distribution of peripheral blood mononuclear cells (PBMCs) is altered in paraneoplastic opsoclonus-myoclonus (POM)...
  12. ncbi request reprint Evidence of cellular immune activation in children with opsoclonus-myoclonus: cerebrospinal fluid neopterin
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, P O Box 19643, Springfield, IL 62702, USA
    J Child Neurol 19:919-24. 2004
    ....
  13. ncbi request reprint Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome
    Michael R Pranzatelli
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
    Pediatrics 115:e115-9. 2005
    ..In addition to clarifying the immune response to B-cell depletion, these data reveal a promising new therapy for OMS that warrants a phase I clinical trial...
  14. pmc Pediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, Department of Neurology, Southern Illinois University School of Medicine, P O Box 19643, Springfield, IL 62794 9643, USA
    J Interferon Cytokine Res 33:523-8. 2013
    ..These data allow investigators to select their own kit cytokines, instead of manufacturer-selected cytokines, for greater cost-effectiveness and interpretability. ..
  15. ncbi request reprint CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Neuroimmunology Laboratory, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794 9643, USA Department of Neurology, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794 9643, USA Electronic address
    J Neuroimmunol 266:75-81. 2014
    ..These biochemical data suggest neuronal/axonal injury in some children with OMS without indicators of astrogliosis, and reduction on sufficient immunotherapy. ..
  16. ncbi request reprint Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
    Pediatr Neurol 33:121-6. 2005
    ..These data delineate differences in the central effects of ACTH and corticosteroid therapy, as well as between high and low ACTH doses, and support the integrity of the brain-adrenal axis in pediatric opsoclonus-myoclonus...
  17. ncbi request reprint CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity
    Michael R Pranzatelli
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
    Mov Disord 19:770-7. 2004
    ..Immunophenotyping of CSF lymphocytes by flow cytometry yields valuable clinical information missed by routine studies and allows crucial treatment decisions to be made rapidly...
  18. doi request reprint Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Neuroimmunology Laboratory, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794 9643, USA
    J Neuroimmunol 243:81-8. 2012
    ..These data implicate the chemokine/chemoreceptor pair CXCL13/CXR5 in B cell recruitment to the CNS in OMS. CXCL13 and CXCL12 may serve as reciprocal biomarkers of disease activity, but CXCL13 also had utility as a treatment biomarker...
  19. doi request reprint Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Neuroimmunology Research Laboratory, Department of Neurology, Southern Illinois University School of Medicine, USA
    J Neurol Sci 326:53-8. 2013
    ..To test for hypothesized disease- and treatment-induced changes in cytokines and adhesion molecules in children with opsoclonus-myoclonus syndrome (OMS)...
  20. doi request reprint CCR4 agonists CCL22 and CCL17 are elevated in pediatric OMS sera: rapid and selective down-regulation of CCL22 by ACTH or corticosteroids
    Michael R Pranzatelli
    Neuroimmunology Research Laboratory, National Pediatric Myoclonus Center, Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL 62794 9643, USA
    J Clin Immunol 33:817-25. 2013
    ..To study the role of Th2-attracting chemokines in opsoclonus-myoclonus syndrome (OMS), a serious neurological paraneoplastic disorder in need of better immunological understanding and therapy...
  21. doi request reprint Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Neuroimmunology Laboratory, Southern Illinois University School of Medicine, Springfield, IL 62794 9643, USA
    Cytokine 53:384-9. 2011
    ..These data reveal a major role for BAFF in peripheral B cell repopulation following rituximab-induced B-cell depletion, and novel changes in CXCL13. ClinicalTrials.gov NCT0024436...
  22. ncbi request reprint Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia
    Michael R Pranzatelli
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62702, USA
    Pediatr Neurol 27:384-7. 2002
    ..They underscore the need to search for unique autoantibodies, as well as cellular mechanisms of pediatric paraneoplastic disease...
  23. doi request reprint Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus
    Michael R Pranzatelli
    Division of Child and Adolescent Neurology, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
    Pediatr Neurol 45:27-33. 2011
    ..However, flow cytometry provides a more sensitive measure of B-cell infiltration. Cerebrospinal fluid oligoclonal bands warrant monitoring in long-term follow-up studies of disease-modifying drugs for opsoclonus-myoclonus...
  24. doi request reprint Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome
    Michael R Pranzatelli
    National Pediatric Myoclonus Center and Neuroimmunology Laboratory, Department of Neurology, Division of Child and Adolescent Neurology, 751 N Rutledge, Suite 3504, P O Box 19643, Springfield, IL 62794 9643, USA
    Cytokine 44:26-32. 2008
    ..The novel dose-related central and peripheral anti-BAFF properties of ACTH, especially, have implications for other BAFF-related autoimmune disorders, infectious diseases, and cancers...
  25. doi request reprint Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus
    Michael R Pranzatelli
    Southern Illinois University School of Medicine, Springfield, IL, USA
    Pediatr Blood Cancer 58:988-91. 2012
    ..No further relapses have occurred in 3 years, but he remains on low-dose ACTH with neuropsychiatric residuals of OMS...
  26. ncbi request reprint Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone
    Michael R Pranzatelli
    National Pediatric Myoclonus Center, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794 9643, USA
    J Pediatr 147:372-8. 2005
    ..Parents of children with opsoclonus-myoclonus syndrome (OMS) frequently describe poor sleep and rage attacks. We hypothesized that these manifestations are related and could result from underlying monoaminergic dysfunction...